You are viewing the site in preview mode

Skip to main content

Advertisement

Articles

Page 4 of 37

  1. Content type: Research article

    In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, ...

    Authors: Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun (Nicole) Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim and Scot Ebbinghaus

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:39

    Published on:

  2. Content type: Research article

    Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic...

    Authors: Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger, Karl-Josef Kallen…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:38

    Published on:

  3. Content type: Research article

    The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT).

    Authors: Sung-Eun Lee, Ji-Young Lim, Tae Woo Kim, Da-Bin Ryu, Sung Soo Park, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee and Chang-Ki Min

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:35

    Published on:

  4. Content type: Research article

    The role of programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) in triple negative breast cancer (TNBC) remains to be fully understood. In this study, we investigated the role of PD-1...

    Authors: Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Clara Chong Hui Ong, Aye Aye Thike, Wei Hseun Yeap, Yi Yang, Ansel Yi Herh Lim, Timothy Kwang Yong Tay, Jin Liu, Siew-Cheng Wong, Jinmiao Chen, Elaine Hsuen Lim, Jabed Iqbal, Rebecca Dent…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:34

    Published on:

  5. Content type: Research article

    Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic ef...

    Authors: Andressa S. Laino, B. C. Betts, A. Veerapathran, I. Dolgalev, A. Sarnaik, S. N. Quayle, S. S. Jones, J. S. Weber and David M. Woods

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:33

    Published on:

  6. Content type: Research article

    Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and...

    Authors: Juan J. Miret, Paul Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y. Li, Yujiro Naito, Min Wu, Venkat S. Malladi, Wei Huang, William Walker, Sangeetha Palakurthi, Glenn Dranoff, Peter S. Hammerman, Chad V. Pecot, Kwok-Kin Wong and Esra A. Akbay

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:32

    Published on:

  7. Content type: Research article

    Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI.

    Authors: Hamzah Abu-Sbeih, Tenglong Tang, Yang Lu, Selvi Thirumurthi, Mehmet Altan, Amir A. Jazaeri, Ramona Dadu, Emmanuel Coronel and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:31

    Published on:

  8. Content type: Research article

    We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroes...

    Authors: Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:30

    Published on:

  9. Content type: Research article

    Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunothe...

    Authors: Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:29

    Published on:

  10. Content type: Research article

    Tumor specific Th9 cells are potential effector cells for adoptive therapy of human cancers. TNF family members OX40L, TL1A and GITRL have been shown to promote the induction of Th9 cells and antitumor immunit...

    Authors: Yuxue Jiang, Jintong Chen, Enguang Bi, Yinghua Zhao, Tianxue Qin, Yiming Wang, Alison Wang, Sujun Gao, Qing Yi and Siqing Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:28

    Published on:

  11. Content type: Research article

    Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expressio...

    Authors: Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:27

    Published on:

  12. Content type: Commentary

    Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) admi...

    Authors: Howard L. Kaufman and Praveen K. Bommareddy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:26

    Published on:

  13. Content type: Research article

    The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer va...

    Authors: Elham Beyranvand Nejad, Robert B. Ratts, Eleni Panagioti, Christine Meyer, Jennifer D. Oduro, Luka Cicin-Sain, Klaus Früh, Sjoerd H. van der Burg and Ramon Arens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:25

    Published on:

  14. Content type: Research article

    Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.

    Authors: Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji and Kohei Shitara

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:24

    Published on:

  15. Content type: Research article

    Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imag...

    Authors: Matthew Scarpelli, Christopher Zahm, Scott Perlman, Douglas G. McNeel, Robert Jeraj and Glenn Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:23

    Published on:

  16. Content type: Short report

    Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when...

    Authors: Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet-Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou, Gilles Paintaud and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:22

    Published on:

  17. Content type: Research article

    Transient depletion of CD4+ T cells results in tumor suppression and survival benefit in murine models; however, the tumor progression and recurrence still occur over more long-term monitoring of mice. Thus, we e...

    Authors: Chang-Yu Chen, Satoshi Ueha, Yoshiro Ishiwata, Shoji Yokochi, De Yang, Joost J. Oppenheim, Haru Ogiwara, Shigeyuki Shichino, Shungo Deshimaru, Francis H. W. Shand, Shiro Shibayama and Kouji Matsushima

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:21

    Published on:

  18. Content type: Research article

    Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to...

    Authors: Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:20

    Published on:

  19. Content type: Research article

    Oncolytic virus (OV)-based therapies have an emerging role in the treatment of solid tumors, involving both direct cell lysis and immunogenic cell death. Nonetheless, tumor-associated stroma limits the efficac...

    Authors: Jana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, Maria D. Ramos, Martí Farrera-Sal and Ramon Alemany

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:19

    Published on:

  20. Content type: Research article

    PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-...

    Authors: Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:18

    Published on:

  21. Content type: Research article

    The advents of novel immunotherapies have revolutionized the treatment of cancer. Adoptive cellular therapies using chimeric antigen receptor T (CAR-T) cells have achieved remarkable clinical responses in B ce...

    Authors: Junlin Yao, Dalam Ly, Dzana Dervovic, Linan Fang, Jong Bok Lee, Hyeonjeong Kang, Yu-Hui Wang, Nhu-An Pham, Hongming Pan, Ming-Sound Tsao and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:17

    Published on:

  22. Content type: Research article

    Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a n...

    Authors: Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:16

    Published on:

  23. Content type: Research article

    Clinical benefit from checkpoint inhibitors has been associated in a tumor-agnostic manner with two main tumor traits. The first is tumor antigenicity, which is typically measured by tumor mutation burden, mic...

    Authors: Patrick Danaher, Sarah Warren, SuFey Ong, Nathan Elliott, Alessandra Cesano and Sean Ferree

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:15

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:76

  24. Content type: Research article

    Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-ex...

    Authors: S. J. Santegoets, C. L. Duurland, E. S. Jordanova, J. J. van Ham, I. Ehsan, S. L. van Egmond, M. J. P. Welters and S. H. van der Burg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:14

    Published on:

  25. Content type: Research article

    The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung c...

    Authors: Katey S. S. Enfield, Spencer D. Martin, Erin A. Marshall, Sonia H. Y. Kung, Paul Gallagher, Katy Milne, Zhaoyang Chen, Brad H. Nelson, Stephen Lam, John C. English, Calum E. MacAulay, Wan L. Lam and Martial Guillaud

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:13

    Published on:

  26. Content type: Research article

    We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic di...

    Authors: Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John J. Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun-Wook Lee, Vijay Kasturi, Kevin Chin, Anja von Heydebreck and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:12

    Published on:

  27. Content type: Short report

    Expression of PDL1 on the surface of tumor cells can blunt the efficacy of many cancer immunotherapies. For example, our lab has previously shown that tumors derived from malignant cells incapable of expressin...

    Authors: Mee Y. Bartee, Parker C. Dryja and Eric Bartee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:11

    Published on:

  28. Content type: Research article

    Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However,...

    Authors: Aurelie Hanoteau, Jared M. Newton, Rosemarie Krupar, Chen Huang, Hsuan-Chen Liu, Angelina Gaspero, Robyn D. Gartrell, Yvonne M. Saenger, Thomas D. Hart, Saskia J. Santegoets, Damya Laoui, Chad Spanos, Falguni Parikh, Padmini Jayaraman, Bing Zhang, Sjoerd H. Van der Burg…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:10

    Published on:

  29. Content type: Research article

    Mismatch Repair Deficiency (MMR-D)-related tumors are highly immunogenic and constitute ideal vaccination targets. In a proof-of-concept study delayed tumorigenesis and prolonged survival has been shown in a c...

    Authors: Claudia Maletzki, Leonie Wiegele, Ingy Nassar, Jan Stenzel and Christian Junghanss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:8

    Published on:

  30. Content type: Research article

    High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients. However, discovery of suitable therapeutic TCR genes is hamp...

    Authors: Junko Matsuzaki, Takemasa Tsuji, Thinle Chodon, Courtney Ryan, Richard C. Koya and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:7

    Published on:

  31. Content type: Review

    Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia vir...

    Authors: Zong Sheng Guo, Binfeng Lu, Zongbi Guo, Esther Giehl, Mathilde Feist, Enyong Dai, Weilin Liu, Walter J. Storkus, Yukai He, Zuqiang Liu and David L. Bartlett

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:6

    Published on:

  32. Content type: Research article

    Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonis...

    Authors: Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig and Manuel Schmidt

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:5

    Published on:

  33. Content type: Case report

    With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments ...

    Authors: Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe and Frances A. Collichio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:4

    Published on:

  34. Content type: Research article

    Thyroid cancer and thyroid autoimmunity are considered opposite extremes of immune-responses. However, several studies have suggested that thyroid cancer coexists with autoimmune thyroid diseases like Hashimot...

    Authors: Shahnawaz Imam, Pervaiz Dar, Rodis Paparodis, Khalil Almotah, Ahmed Al-Khudhair, Syed Abdul-Moiz Hasan, Nancy Salim and Juan Carlos Jaume

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:3

    Published on:

  35. Content type: Short report

    The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the ef...

    Authors: Omar Mamlouk, Umut Selamet, Shana Machado, Maen Abdelrahim, William F. Glass, Amanda Tchakarov, Lillian Gaber, Amit Lahoti, Biruh Workeneh, Sheldon Chen, Jamie Lin, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Nizar Tannir…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:2

    Published on:

  36. Content type: Case report

    Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being tre...

    Authors: Christopher C. Frohne, Ernesto M. Llano, Ashley Perkovic, Russell D. Cohen and Jason J. Luke

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:1

    Published on:

  37. Content type: Research article

    Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The prognosis in the metastatic (m) setting is poor. Programmed...

    Authors: A. Boilève, M. I. Carlo, P. Barthélémy, S. Oudard, D. Borchiellini, M. H. Voss, S. George, C. Chevreau, J. Landman-Parker, M-D Tabone, D. D. Chism, A. Amin, M. A. Bilen, D. Bosse, A. Coulomb-L’hermine, Xiaoping Su…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:159

    Published on:

  38. Content type: Research article

    PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune syste...

    Authors: Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson and Simon T. Barry

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:158

    Published on:

  39. Content type: Commentary

    Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype. Melanoma and lung cancer demon...

    Authors: Saman Maleki Vareki

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:157

    Published on:

  40. Content type: Case report

    The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of induced immune mucositis and esophagitis is extremely rare.

    Authors: Alice Horisberger, Stefano La Rosa, Jean-Philippe Zurcher, Stefan Zimmermann, Francois Spertini, George Coukos and Michel Obeid

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:156

    Published on:

  41. Content type: Research article

    Immune-checkpoint inhibitors plus chemotherapy are emerging as effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), but little is known about the magnitude of benefits and potentia...

    Authors: Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:155

    Published on:

  42. Content type: Commentary

    Immune checkpoint inhibitors which activate the host’s immune system to fight cancer have brought dramatic improvements to the overall survival of a growing number of deadly malignancies. Their use comes at th...

    Authors: Khashayar Esfahani

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:154

    Published on:

  43. Content type: Case report

    Neurologic toxicities with immune therapy are rare, but can cause devastating and often permanent injury when they occur. Although there is increasing interest in the potential synergism between immune therapy...

    Authors: Victoria A. Chang, Daniel R. Simpson, Gregory A. Daniels and David E. Piccioni

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:153

    Published on:

  44. Content type: Research article

    Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the...

    Authors: Christina Jensen, Daniel Hargbøl Madsen, Morten Hansen, Henrik Schmidt, Inge Marie Svane, Morten Asser Karsdal and Nicholas Willumsen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:152

    Published on:

  45. Content type: Research article

    Tumor-associated macrophages (TAMs) facilitate tumor progression via establishment of an immunosuppressive tumor microenvironment (TME). However, it is poorly understood how tumor cells could functionally modu...

    Authors: Zhi-Fa Wen, Hongxiang Liu, Rong Gao, Meng Zhou, Jie Ma, Yue Zhang, Jinjin Zhao, Yongqiang Chen, Tianyu Zhang, Fang Huang, Ning Pan, Jinping Zhang, Bernard A. Fox, Hong-Ming Hu and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:151

    Published on:

  46. Content type: Case report

    Immune checkpoint inhibitors have revolutionized treatment and improved survival in many cancers. However, since immune-related adverse events (irAEs) are potentially fatal, early recognition and prompt treatm...

    Authors: Cecilia Monge, Hoyoung Maeng, Alessandra Brofferio, Andrea B. Apolo, Bharath Sathya, Andrew E. Arai, James L. Gulley and Marijo Bilusic

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:150

    Published on:

  47. Content type: Research article

    Simultaneous blockade of immune checkpoint molecules and co-stimulation of the TNF receptor superfamily (TNFRSF) is predicted to improve overall survival in human cancer. TNFRSF co-stimulation depends upon coo...

    Authors: George Fromm, Suresh de Silva, Kellsey Johannes, Arpita Patel, Josiah C. Hornblower and Taylor H. Schreiber

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:149

    Published on:

  48. Content type: Research article

    Tumor cell mediated immune-suppression remains a question of interest in tumor biology. In this study, we focused on the metabolites that are released by prostate cancer cells (PCC), which could potentially at...

    Authors: Yutao Yan, Lei Chang, Hongzhe Tian, Lu Wang, Yawei Zhang, Tao Yang, Guohao Li, Weifeng Hu, Kavita Shah, Gang Chen and Yonglian Guo

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:148

    Published on:

  49. Content type: Case report

    Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of ac...

    Authors: Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:147

    Published on:

Annual Journal Metrics

Advertisement